Changes

Jump to: navigation, search

Erdafitinib (Balversa)

43 bytes added, 10 January
m
no edit summary
==History of changes in FDA indication==
*4/12/2019: [https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer Accelerated FDA approval] for adult patients with locally advanced or metastatic [[Bladder_cancer|urothelial carcinoma]] that has susceptible [[Biomarkers#FGFR3|FGFR3]] or [[Biomarkers#FGFR2|FGFR2]] [[Biomarkers#Alterations|genetic alterations]] and progressed during or following at least one line of prior [[Regimen_classes#Platinum-based_regimen|platinum-containing chemotherapy ]] including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
==Also known as==
LookupUsers, editors, emailconfirmed
24,195
edits

Navigation menu